



We want the UK to be the **best place in the world** to research, develop and use the **medicines and vaccines of the future**

Our **10-year strategy**



- ◆ UK in top quartile of health systems for access and uptake
- ◆ Increased medicines uptake with measurable impact on outcomes
- ◆ Medicines spend grows in line with patient demand
- ◆ New payment models recognise long-term value of innovative therapies

Ensure value, access and uptake of innovative medicines and vaccines, now and in the future



**Improve UK attractiveness
for industry research,
development and
manufacturing**



- ◆ UK reaches 2.4% GDP target for R&D and increases share of manufacturing for innovative medicines
- ◆ Recognition that R&D and manufacturing is vital to the economy
- ◆ Clinical research performance continues to improve
- ◆ UK retains global R&D thought leadership

- ◆ Industry viewed as a true partner to the NHS
- ◆ Cross-sector collaborations benefitting patients, the NHS and the economy
- ◆ Increase in value of UK life sciences

Build better partnerships between industry and NHS and across Life Sciences sector





- Fully integrated NHS data sets, well governed and accessible to industry
- UK is more attractive for cutting-edge research collaboration and evidence generation

Improve UK's health data capability and industry's access to data



Provide international leadership and drive global policy

- ◆ Regulatory and trade environments are positively influenced through driving global policy
- ◆ ABPI and UK affiliates seen as key to shaping UK view on international issues
- ◆ ABPI and our members shape UK policy on international issues



Build a stronger industry reputation in the UK

- ◆ Government, NHS, healthcare professionals and patients will advocate for the pharmaceutical industry
- ◆ Government confident in championing the sector



We want the UK to be the **best place in the world** to research, develop and use the **medicines and vaccines of the future**

Our 10-year strategy

